Physician profile
Eric Alan Wechsler
NPI 1659469526
$36,074.04
in general payments reported to CMS, 2019-2025
48 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,976 · 2021: $993 · 2022: $1,429 · 2023: $2,355 · 2024: $2,856 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $7,373 · Travel and Lodging: $389 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,400.00 |
| Food and Beverage | $7,372.83 |
| Travel and Lodging | $389.29 |
| Education | $186.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13,198.04 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $11,226.20 | 2022-2025 | Shingrix, Benlysta |
| Astrazeneca Pharmaceuticals LP | $1,137.73 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,096.09 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $939.50 | 2019-2025 | Jynarque |
| Amgen INC. | $782.14 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $635.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.88 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $542.49 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $453.31 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $427.36 | 2019-2023 | Auryxia |
| Mallinckrodt Hospital Products INC. | $415.50 | 2024-2025 | Acthar |
| Ardelyx, INC. | $403.96 | 2024-2025 | Ibsrela |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $398.17 | 2021-2025 | Lupkynis |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $385.09 | 2019-2024 | Rayaldee |
| Novo Nordisk INC | $359.72 | 2023-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $348.43 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $333.19 | 2019-2025 | Ultomiris |
| Amarin Pharma, INC. | $237.74 | 2019-2021 | |
| Travere Therapeutics, INC. | $171.01 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $155.35 | 2025 | Empaveli |
| Viiv Healthcare Company | $149.60 | 2023 | Dovato, Rukobia |
| Abbvie INC. | $130.72 | 2023 | Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $97.26 | 2022-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $96.36 | 2019-2024 | Oxlumo |
| Daiichi Sankyo INC. | $92.04 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $88.98 | 2019-2020 | |
| Recor Medical INC | $82.82 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Amag Pharmaceuticals, INC. | $82.09 | 2020-2021 | |
| Theratechnologies INC. | $65.78 | 2023 | Egrifta, Trogarzo |
| Genzyme Corporation | $65.47 | 2019-2023 | |
| Lundbeck LLC | $52.48 | 2020 | |
| Scpharmaceuticals INC. | $47.97 | 2025 | |
| Azurity Pharmaceuticals, INC. | $44.43 | 2025 | Edarbi |
| Exact Sciences Corporation | $40.41 | 2023-2024 | Cologuard Collection Kit |
| Shionogi INC | $39.18 | 2023 | Fetroja |
| Janssen Pharmaceuticals, INC | $36.43 | 2019-2024 | Xarelto |
| Shield Therapeutics INC | $34.36 | 2022 | |
| Lilly USA, LLC | $32.97 | 2024 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $32.34 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.94 | 2025 | Tryvio |
| Kyowa Kirin, INC. | $25.15 | 2025 | |
| Mallinckrodt Enterprises LLC | $24.65 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.02 | 2024 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $20.09 | 2022 | |
| La Jolla Pharmaceutical Company | $13.32 | 2019 | |
| Allergan, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wechsler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.